Peregrine Pharmaceuticals reported $-2684000 in Operating Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Amgen AMGN:US USD 2.23B 508M
AstraZeneca AZN:LN USD 1.09B 151M
Biocryst Pharmaceuticals BCRX:US USD -46311000 28.87M
Bristol Myers Squibb BMY:US USD 1.94B 528M
Celldex Therapeutics CLDX:US USD -27885000 189K
Eli Lilly And LLY:US USD 1.84B 159.9M
GlaxoSmithKline GSK:LN GBP 1.87B 677M
Immunogen IMGN:US USD -59559000 17.87M
Intrexon XON:US USD -21797000 14.18M
Karyopharm Therapeutics KPTI:US USD -33869000 3.03M
Macrogenics MGNX:US USD 11.98M 36.94M
Mannkind MNKD:US USD -12790000 3.18M
Merk MRK:US USD 3.51B 505M
Minerva Neurosciences NERV:US USD -5070000 137K
Newlink Genetics NLNK:US USD -8835000 1.28M
Novartis NOVN:VX USD 1.95B 219M
Novavax NVAX:US USD -243879000 116.69M
Repligen RGEN:US USD 48.84M 3.83M
Roche Holding ROG:VX 5.93B 5.62B
Xencor XNCR:US USD -42693000 4.34M